Search

Background. Primary cutaneous lymphomas (PCL) comprise a heterogeneous group of neoplasms of mature lymphocytes with skin tropism. Although, by definition, these lymphomas are restricted to the skin at the time of diagnosis, during the course of the disease it may involve also lymph nodes and visceral organs. A close cooperation between a dermatologist and oncologist is required to ensure proper treatment. We present in a real-life data on treatment of patients with PCL between dermatology and oncology department. Material and methods. 104 patients were registered in a joined database of Oncology Department of Oncology Centre in Bydgoszcz and Dermatology Department of Medical University in Torun between 2007 and 2017. Due to different clinical and prognostic features data from MF/SS (44 patients), non-MF/SS CTCLs and CBCLs were presented separately. Results. Median overall survival for patients with MF/SS was 76.7 months. Median follow-up time was 5 years.

Background/aim Malignant melanoma is a rare disease in the pediatric population and there are no recommendations regarding its management in children, while the current standard of care in metastatic or unresectable melanoma in adult patients includes immunotherapy (anti-CTLA-4 and anti-PD-1 antibodies). Advances in the management of adults with melanoma offer the prospect of promising therapeutic options for children. Case report We describe a case of a 7-year-old patient with recurrent metastatic melanoma, for whom pembrolizumab was used as an adjuvant therapy on compassionate use basis. Conclusion Due to adverse events, the treatment was discontinued after 5 months of pembrolizumab, but with 12-months of follow-up, patient remains in complete remission.

e22166 Background: Currently solid tumor response is based on anatomic measurements as defined by RECIST criteria. 18F-FLT is a PET tracer that allows imagining of cell proliferation rate. Imaging ...